Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Venmax Drugs And Pharmaceuticals Ltd (531015)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531015 NSE: Pharmaceuticals & Drugs | Small Cap | Venmax Drugs&Pharma Share Price
₹15.01 -0.89 (-5.60%)
As on 25-Sep'26 16:59
Venmax Drugs And Pharmaceuticals Ltd (531015)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531015 NSE: Pharmaceuticals & Drugs | Small Cap | Venmax Drugs&Pharma Share Price
₹15.01 -0.89 (-5.60%)
As on 25-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹23 Cr.
Current Price
₹15
52-Week Low / High
₹13 / 31
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
55
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
10.46%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹14.5 Cr.
Face Value
₹10
All Time Low / High
₹1.10 / 36.96
Check Before You Invest
M-Cap below 100cr DeciZen not available
Is Venmax Drugs And Pharmaceuticals Ltd a good quality company?
Venmax Drugs And Pharmaceuticals Ltd is a quality company, based on a multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Venmax Drugs And Pharmaceuticals Ltd performance compare with that of its Peers?
Revenue growth of Venmax Drugs And Pharmaceuticals Ltd vs industry peers?
Venmax Drugs And Pharmaceuticals Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Venmax Drugs And Pharmaceuticals Ltd?
Promoters hold 10.46% of the Venmax Drugs And Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Venmax Drugs And Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 19.8% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Venmax Drugs And Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -7.3% | -140.9% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.6% | - |
| Value Creation Index ⓘ | -1.5 | NA | NA | NA | NA | NA | NA | NA | NA | NA | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 1.9 | 0.3 | 0 | 0.2 | 0.5 | 0.2 | 0 | 0 | 0 | 0.8 | 9 |
| Sales YoY Gr. | - | -86.5% | -100% | NA | 213.3% | -63.8% | -100% | NA | NA | NA | - |
| Adj EPS ⓘ | -0.3 | -1.4 | -0.5 | -0.5 | -0.5 | -0.3 | 3.5 | 0.4 | 0.1 | -0 | 0.2 |
| YoY Gr. | - | NA | NA | NA | NA | NA | NA | -87.8% | -72.1% | -116.7% | - |
| BVPS (₹) ⓘ | 0.4 | -3.6 | -4 | -4.5 | -5 | -5.3 | -1.8 | -1.4 | -1.2 | -1.3 | 14.4 |
| Adj Net Profit ⓘ | -0.1 | -0.7 | -0.2 | -0.2 | -0.3 | -0.2 | 1.9 | 0.2 | 0.1 | -0 | 0 |
| Cash Flow from Ops. ⓘ | -0.2 | -1.1 | -0.3 | -0.1 | -0.3 | 0.3 | 1.9 | -0 | 0 | -2.3 | - |
| Debt/CF from Ops. ⓘ | -9.2 | -1.8 | -8 | -47.1 | -9 | 8.8 | 0.2 | -113.6 | 160.1 | -0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -9.2% | 11.5% | NA | NA | ||||
| Adj EPS ⓘ | NA | NA | -117.8% | -116.7% | ||||
| BVPSⓘ | -214.3% | NA | NA | NA | ||||
| Share Price | 19.2% | 29.1% | 53.1% | -35.4% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -51.5 | 89.1 | 12.2 | 10.6 | 11 | 6 | -99.1 | -27.3 | -9.5 | -0.6 | 2.9 |
| Op. Profit Mgn % ⓘ | -7.1 | -237.6 | 0 | -157.8 | -53.9 | -198.2 | 0 | 0 | 0 | -131.3 | 1.7 |
| Net Profit Mgn % ⓘ | -7.1 | -287.3 | 0 | -156.8 | -57.9 | -96.8 | 0 | 0 | 0 | -1.3 | 3 |
| Debt to Equity ⓘ | 8.7 | -1 | -1 | -1 | -1 | -0.8 | -0.4 | -0.5 | -0.5 | -0.1 | 0 |
| Working Cap Days ⓘ | 430 | 1,303 | 0 | 339 | 219 | 539 | 0 | 0 | 0 | 601 | 759 |
| Cash Conv. Cycle ⓘ | 13 | 93 | 0 | -85 | -55 | -729 | 0 | 0 | 0 | 81 | 499 |
Valuation of Venmax Drugs&Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Venmax Drugs And Pharmaceuticals Ltd FAQs
The current trading price of Venmax Drugs&Pharma on 25-Sep-2026 16:59 is ₹15.01.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 24-Sep-2026 the market cap of Venmax Drugs&Pharma stood at ₹23.03 Cr
The latest P/E ratio of Venmax Drugs&Pharma as of 24-Sep-2026 is 81.96.
The latest P/B ratio of Venmax Drugs&Pharma as of 24-Sep-2026 is 1.11.
The 52-week high of Venmax Drugs&Pharma is ₹31.49 and the 52-week low is ₹12.71.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Venmax Drugs&Pharma is ₹9.29 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Venmax Drugs And Pharmaceuticals Ltd is a below average quality company.
The key valuation ratios of Venmax Drugs And Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Venmax Drugs And Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Venmax Drugs And Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals is a public limited company incorporated under Companies Act, 1956 and domiciled in India. The company was initially incorporated as private limited company under the name and style of ‘Yenkay Medico Private Limited’, on September 28, 1998. The company thereafter changed its name to ‘Yenkey Drugs & Pharmaceuticals Private Limited’ on January 18, 1995. The company has become a public limited company on February 3, 1995 with ‘Yenkey Drugs & Pharmaceuticals Ltd’. Finally, the company has changed its name to ‘Venmax Drugs & Pharmaceuticals Ltd’ on April 13, 2009.
The company is engaged in the business of pharmaceutical products, drug intermediates, and Active Pharmaceutical Ingredients (APIs). It is currently developing oncology products in its R&D division. The company is planning to establish a cGMP-compliant manufacturing unit in the Pharma Cluster at Hyderabad to meet export demand.
Business area of the company
Venmax Drugs and Pharmaceuticals is engaged in the business of pharmaceutical products, drug intermediates, and active pharmaceutical ingredients.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
